Trial Profile
A Phase 2 Study of Anlotinib in Subjects With Steroid Depenent/Refractory Chronic Graft Versus Host Disease(cGVHD)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Mar 2021
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 22 Mar 2021 Status changed from not yet recruiting to discontinued.
- 22 Jan 2020 New trial record